NL0011832936
© Newsfile
03.12.2025
COPN
LISTED
SIX
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
News Preview
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo an...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2025
COPN
LISTED
SIX
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
News Preview
Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged tw...
Themefolio
Profiler
Peergroup
© Newsfile
11.11.2025
COPN
LISTED
SIX
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
News Preview
Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo̵...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
03.11.2025
COPN
LISTED
SIX
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
News Preview
Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
21.10.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
News Preview
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults an...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
News Preview
Dublin, Ireland--(Newsfile Corp. - October 7, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgari...
Themefolio
Profiler
Peergroup
© Newsfile
27.08.2025
COPN
LISTED
SIX
Cosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-Examination
News Preview
Dublin, Ireland--(Newsfile Corp. - August 27, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending European approval of...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2025
COPN
LISTED
SIX
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
News Preview
Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE: 4502) (NYSE: TAK), to produce Mesalazine MMX 1200 mg (marketed as Liald...
Themefolio
Profiler
Peergroup
© Newsfile
23.07.2025
COPN
LISTED
SIX
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
News Preview
Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
COPN
LISTED
SIX
Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia
News Preview
Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with H...
Themefolio
Profiler
Peergroup
© Newsfile
16.07.2025
COPN
LISTED
SIX
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
News Preview
Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact....
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
COPN
LISTED
SIX
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation.Dublin, Ireland--(Newsfile Corp. - July 1, 2025) - Cosmo N.V. (SIX: COPN), a global leader in AI-driven h...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
25.06.2025
COPN
LISTED
SIX
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
News Preview
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by...
Themefolio
Profiler
Peergroup
© Newsfile
24.06.2025
COPN
LISTED
SIX
Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center
News Preview
Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software application connecting the Medtronic GI Genius™ intelligent endoscopy module, an AI-powered platform for gastrointestinal e...
Themefolio
Profiler
Peergroup
© Newsfile
30.05.2025
COPN
LISTED
SIX
Voting Results of Cosmo's 2025 AGM
News Preview
Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of sha...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2025
COPN
LISTED
SIX
Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025
News Preview
Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2025
COPN
LISTED
SIX
Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem
News Preview
Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification[1] for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Qu...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)
News Preview
Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals N.V. (SIX: COPN) confirms that its financial guidance for 2025 remains unchanged. While the company is disappointe...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2025
COPN
LISTED
SIX
Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application (MAA) for...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2025
COPN
LISTED
SIX
Cosmo Publishes Agenda of AGM 2025
News Preview
Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Nether...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2025
COPN
LISTED
SIX
Cosmo Appoints Federico Sommariva as Chief Legal Counsel
News Preview
Dublin, Ireland--(Newsfile Corp. - April 1, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management...
Themefolio
Profiler
Peergroup
© Newsfile
21.03.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals publishes Annual Report 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March...
Themefolio
Profiler
Peergroup
© Newsfile
06.03.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR FY 2024 Revenue of €266.8 million (unaudited) reaching upper end of guidance FY 2024 Operating Profit (unaudited) of €148.9 million, exceeding guidance, when adjusted for an accounting policy change Outlook for 2025...
Themefolio
Profiler
Peergroup
© Newsfile
12.02.2025
COPN
LISTED
SIX
Cosmo to Host Investor Day on April 9, 2025
News Preview
Dublin, Ireland--(Newsfile Corp. - February 12, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce that it will host an Investor Day on Wednesday, April 9, 2025. The live event will be held at the Hotel “Park Hyatt” at Beethovenstrasse 21 in 8002 Zurich, S...
Themefolio
Profiler
Peergroup
© Newsfile
11.02.2025
COPN
LISTED
SIX
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
News Preview
Dublin, Ireland--(Newsfile Corp. - February 11, 2025) - Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Inte...
Themefolio
Profiler
Peergroup
© Newsfile
10.02.2025
COPN
LISTED
SIX
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
News Preview
Dublin, Ireland, and Mumbai, India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2025
COPN
LISTED
SIX
Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025
News Preview
Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET. Live conference call and video webcast presentation: Cosmo invites investors...
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
News Preview
Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength: Year-end cash and short-term investments of €170.4 million, reflecting a robust balance sheet with zero debt....
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Appoints Chief Strategy Officer
News Preview
Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2024
COPN
LISTED
SIX
Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM
News Preview
Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024. Co...
Themefolio
Profiler
Peergroup
© Newsfile
11.10.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Appoints New Chief Financial Officer
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall D...
Themefolio
Profiler
Peergroup
© Newsfile
23.09.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development
News Preview
Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With ex...
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures
News Preview
Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in &#...
Themefolio
Profiler
Peergroup
© Newsfile
31.07.2024
COPN
LISTED
SIX
Cosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA Clearance
News Preview
Dublin, Ireland--(Newsfile Corp. - July 31, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510...
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2024
COPN
LISTED
SIX
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtron...
Themefolio
Profiler
Peergroup
© Newsfile
09.07.2024
COPN
LISTED
SIX
Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024
News Preview
Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live vi...
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2024
COPN
LISTED
SIX
Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting
News Preview
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year Shareholders approved all other proposals of the Board of Directors, including the adoption of the FY2023 annual accounts and updates to the remuneration policy of the Company...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
COPN
LISTED
SIX
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
News Preview
Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innov...
Themefolio
Profiler
Peergroup
© Newsfile
03.06.2024
COPN
LISTED
SIX
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX
News Preview
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its...
Themefolio
Profiler
Peergroup
© Newsfile
01.06.2024
COPN
LISTED
SIX
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its final audited results for the financial year 2023. Financial highlights As previously announced when publishing preliminar...
Themefolio
Profiler
Peergroup
© Newsfile
24.05.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting
News Preview
Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in the share capital of Cosmo were represented at this...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2024
COPN
LISTED
SIX
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulat...
Themefolio
Profiler
Peergroup
© Newsfile
25.04.2024
COPN
LISTED
SIX
Cosmo Announces Leadership Changes
News Preview
Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed as new Chairman of the Board. Incumbent Chairman Mauro Ajani to continue as a Board member. Additiona...
Themefolio
Profiler
Peergroup
© Newsfile
12.04.2024
COPN
LISTED
SIX
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
News Preview
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling...
Themefolio
Profiler
Peergroup
© Newsfile
20.03.2024
COPN
LISTED
SIX
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
News Preview
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. Outlook for 2025. Dublin, Ireland--(Newsfile Corp. - March 20, 2024) - Cosmo...
Themefolio
Profiler
Peergroup
© Newsfile
19.03.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
News Preview
Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN), (NSE: SUNPHARMA) (BSE: 524715) (“Sun Pharma”) has announced that the Australian Therape...
Themefolio
Profiler
Peergroup
© Newsfile
25.01.2024
COPN
LISTED
SIX
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
News Preview
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial analysts and busine...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2023
COPN
LISTED
SIX
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
News Preview
Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsi...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
